NCT06925126Not yet recruiting
Exosome-based Recurrence Score for Post-Treatment Ovarian Cancer
Exosome-based Scoring Model for Post-treatment Surveillance of Recurrence in Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 13 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to develop an exosome-based scoring model for post-treatment surveillance of recurrence in ovarian cancer. The main questions it aims to answer are: 1. Does this model have the potential for ovarian cancer recurrence monitoring? 2. Can this model demonstrate superior performance to CA125 for ovarian cancer recurrence monitoring? Participants will : 1. Provide serial blood samples at predefined times 2. Undergo standardized imaging and clinical assessments during follow-up visits
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 6 Apr 2025
- Start date
- Jun 2025
- Primary completion date
- Jun 2027
- Lead sponsor
- Fudan University
- Diseases
- Ovarian cancer
- NCT number
- NCT06925126
What you commit to
- Study type: Observational
- Planned participants: 200
- From Jun 2025 to the primary completion date, Jun 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with history of other malignancies within the past 5 years (except completely resected basal cell carcinoma or squamous cell carcinoma of the skin)
Other
- Patients with non-epithelial tumors
- Women who are pregnant, lactating, or intend to become pregnant during the study period
- Patients who refuse to participate in the study
Who the study is looking for
- Women aged ≥ 18 years
- Pathologic confirmed stage I-IV epithelial ovarian cancer, with ≤2 prior lines of therapy (maintenance therapy is not counted as a line of treatment), platinum-sensitive recurrence (achieved complete/partial response \[CR/PR\] after last platinum-based chemotherapy, with a platinum-free interval \>6 months), and radiologically confirmed recurrent disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- A life expectancy of at least 6 months
- Written informed consent
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.